Press "Enter" to skip to content

1 The retractions came only a few months after BioMed Central cliquez içi.

Charlotte J. Haug, M cliquez içi .D., Ph.D.1 The retractions came only a few months after BioMed Central, an open-access publisher owned by Springer, retracted 43 content for the same reason. How can you really fake peer review? Moon, who studies medicinal vegetation, had set up a straightforward procedure. He gave journals recommendations for peer reviewers for his manuscripts, offering them with e-mail and titles addresses. But these addresses had been ones he created, so the requests to review visited him or his co-workers directly.

Enzalutamide is definitely distinct from the currently available antiandrogen agents in that it inhibits nuclear translocation of the androgen receptor, DNA binding, and coactivator recruitment. In addition, it has a better affinity for the receptor, induces tumor shrinkage in xenograft models , and has no known agonistic effects. Based on these findings, a dose of enzalutamide was recognized for further study.13 In our stage 3 trial, we evaluated whether enzalutamide would prolong life in men with progressive castration-resistant prostate cancer after chemotherapy. The look incorporated the suggestions of the Prostate Cancer Clinical Trials Functioning Group 2 14 in order to avoid premature study-drug discontinuation and to help address previously determined difficulties in assessing outcomes in clinical trials involving guys with prostate cancer.